AAM urges action on biosimilars

The US trade group for generics and biosimilars companies has underlined the steps that the US Food and Drug Administration (FDA) can take to further the adoption of affordable copies of expensive biologic medicines.

The Association for Accessible Medicines (AAM) has submitted written comments to the FDA following a public hearing with the agency this month about how it can facilitate competition under the Biosimilars Action Plan.

In its comments, the AAM calls for the FDA to work with the Department of Health and Human Services to advance incentives to ensure further market penetration and timely adoption of lower-priced, life-saving biosimilars.